One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

Ravulizumab every 8 weeks showed non‐inferiority to eculizumab every 2 weeks in a 26‐week, phase 3, randomized controlled trial in adults with paroxysmal nocturnal hemoglobinuria (PNH) who were clinically stable on eculizumab (NCT03056040). We report results from the first 26 weeks of the extension...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Haematol
Hlavní autoři: Kulasekararaj, Austin G., Hill, Anita, Langemeijer, Saskia, Wells, Richard, González Fernández, F. Ataúlfo, Gaya, Anna, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Mitchell, Lindsay, Usuki, Kensuke, Bosi, Alberto, Brodsky, Robert A., Ogawa, Masayo, Yu, Ji, Ortiz, Stephan, Röth, Alexander, Lee, Jong Wook, Peffault de Latour, Régis
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246907/
https://ncbi.nlm.nih.gov/pubmed/33301613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13564
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky